Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.
about
Anti-vascular endothelial growth factor for proliferative diabetic retinopathyAnti-vascular endothelial growth factor for neovascular glaucomaAnti-vascular endothelial growth factor for proliferative diabetic retinopathyRanibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectivenessStudy of the Effect of Injection Bevacizumab through Various Routes in Neovascular GlaucomaA review of anti-VEGF agents for proliferative diabetic retinopathyTreatment of diabetic retinopathy: Recent advances and unresolved challengesAttenuation of corneal neovascularization by topical low-molecular-weight heparin-taurocholate 7 without bleeding complicationPresence and Risk Factors for Glaucoma in Patients with Diabetes.The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Evolving European guidance on the medical management of neovascular age related macular degeneration.Pharmacotherapies for diabetic retinopathy: present and future.Emerging pharmacotherapies for diabetic macular edema.A proposed new classification for diabetic retinopathy: the concept of primary and secondary vitreopathy.Emerging drugs for diabetic retinopathy.Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis)Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathyIntravitreal bevacizumab for neovascular glaucoma.Increased vitreous shedding of microparticles in proliferative diabetic retinopathy stimulates endothelial proliferationBevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma.Treatment of proliferative diabetic retinopathy with anti-VEGF agents.Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbitsPanretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathyAnti-VEGF Agents for Ocular Angiogenesis and Vascular PermeabilityAntiangiogenic therapy for ischemic retinopathies.Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.Indications for intravitreal bevacizumab in ibadan, sub-saharan Africa.KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularizationRegression of iris neovascularization after subconjunctival injection of bevacizumab.Diabetic retinopathy - An update.Some ethical considerations for the "off-label" use of drugs such as AvastinThe International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.Delayed corneal epithelial healing after intravitreal bevacizumab: a clinical and experimental study.Pars plana Ahmed implantation combined with 23-gauge vitrectomy for refractory neovascular glaucoma in diabetic retinopathy.Vascular Endothelial Growth Factor and Diabetic Retinal Disease.Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications.
P2860
Q24187858-8844DFEE-C0DF-4431-BED3-929690397A09Q24197589-6BAB0C3C-79F5-4D44-A4B1-440D01C349B4Q24236189-0AE95DD3-1BDE-4E7A-BA69-4974D8852A9EQ24674358-8DCECC2D-C050-4F2A-9DD0-E5A3DB5E774EQ26741016-32E7062B-780F-4EDB-8504-71D9E0574C45Q27025643-61FFA4E9-1A25-42D7-8E40-905DA3FDB7D9Q28067491-B7B633D2-C699-4D36-AA35-9DC0E2B4C10DQ28829757-95BA475A-5F9B-4F28-8905-CF9CF4290537Q30244246-CCA0EC35-FB84-4654-9F08-3F21860B8D12Q31061150-58176B39-C84F-47B0-90B7-52A34BBF47FCQ33255038-42606DBE-2694-413D-B993-760FC58C0CA7Q33294882-56ABBD01-6CD7-493E-AB54-28E167A2A447Q33304852-A279B993-A8F2-4033-8125-06DD8635AF3AQ33312306-966B7A07-D57C-4A3C-8A72-EFCC944CFF3BQ33388498-A2E6D8AB-614B-4092-91D6-C7D2ED1A4079Q33416826-28834788-98AB-4D74-A701-18725BA7C847Q33492339-52B50576-155F-451B-A309-7E3FDF6F4EA5Q33512595-67FF1FC9-6E89-4776-B5C4-B8D75BDF91CEQ33518352-A7532E75-49EE-48C3-BA85-B899B75C4FF1Q33571271-B72CE642-2C9D-49C5-8479-8125DEB9AA4FQ33812021-C1E580C8-EBDE-4519-819A-95B6D736BEDCQ33902419-2F5BF076-24A8-47AE-AB37-0D6DEA51EFC6Q33911625-769AED8C-B24D-42B5-9915-1CFE98BFFD99Q33949871-50276531-9964-479D-B4C8-B07289021EE8Q34011852-7F1065D9-4966-4105-8071-E592EB0345A5Q34088274-37CD9867-8248-4749-821B-3CE9EA0368E4Q34295974-B27C5B65-D295-45A2-AB26-332AC634CC67Q34515440-6C9E7F03-A1CF-4185-9A6C-C0B01B499A60Q34627103-8DA41C4C-09C9-44DC-9A41-D5D172BE4C33Q34648669-6A8C829F-B0A0-4628-B270-7955A93B9F7BQ34848892-E01258CB-6A19-40E9-8E68-AE35BAED6FC2Q34889150-50362540-BBFB-49A2-A58F-50717E25C1E4Q34957902-671CFA65-5339-488B-8056-D3681D33F9C2Q35762558-19C01392-3EE4-4BF5-BE24-DC7591072EA8Q35762657-FC64645A-D29F-4BA3-9D9B-656F802C0F22Q35835470-EAD7437B-E10C-4727-9EEF-FD0ED7776167Q35886989-CE3CAFA5-177D-4001-A763-A4B58BE6604EQ35950867-E15D35C5-5AE7-471C-B210-7F600AA29F1EQ35956190-A165EC0D-4F64-4E10-B27C-DD1AA95C9816Q36031547-E29E510D-BF92-4895-A2E4-A8182582D159
P2860
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Regression of retinal and iris ...... vacizumab (Avastin) treatment.
@en
Regression of retinal and iris neovascularization after intravitreal bevacizumab
@nl
type
label
Regression of retinal and iris ...... vacizumab (Avastin) treatment.
@en
Regression of retinal and iris neovascularization after intravitreal bevacizumab
@nl
prefLabel
Regression of retinal and iris ...... vacizumab (Avastin) treatment.
@en
Regression of retinal and iris neovascularization after intravitreal bevacizumab
@nl
P1433
P1476
Regression of retinal and iris ...... vacizumab (Avastin) treatment.
@en
P2093
Robert L Avery
P304
P356
10.1097/00006982-200603000-00016
P577
2006-03-01T00:00:00Z